Global pharmaceutical company Alfasigma S.p.A. announced that it has signed a business transfer agreement with its Chinese partner, Hong Kong Ease Comfort Medical Investment Management Co., Ltd. (Ease Comfort), under which the promotional and management responsibilities for sulodexide in the Chinese market will be transferred back to Alfasigma China.
Deal Snapshot
| Item | Detail |
|---|---|
| Acquirer | Alfasigma S.p.A. (via Alfasigma China) |
| Counterparty | Hong Kong Ease Comfort Medical Investment Management Co., Ltd. (Ease Comfort) |
| Agreement Type | Business transfer agreement |
| Scope | Promotional and management responsibilities for sulodexide in the Chinese market |
| Announcement Date | 4 Nov 2026 |
| Transaction Value | Not disclosed |
| Expected Closing | Not disclosed |
Product Profile – Sulodexide
- Molecule: A highly purified glycosaminoglycan complex composed of an 80 % fast‑moving heparin fraction and a 20 % dermatan sulfate fraction.
- Indication: Treatment of various vascular diseases.
- Global Footprint: Approved in over 30 countries and regions worldwide.
- China Positioning: A core legacy asset now moving from partner‑led promotion to direct in‑house commercialization by Alfasigma China.
Financial Impact & Strategic Outlook
- Revenue Accretion: The business adjustment is expected to generate approximately €25 million in incremental annual revenue for Alfasigma China.
- Scale Expansion: The move will expand Alfasigma China’s business scale by around 30 %.
- Strategic Milestone: The transaction supports the company’s strategic goal of growing into an organization with annual revenues exceeding €100 million starting in 2027.
- Commercial Rationale: Internalizing promotion of an established, widely approved vascular franchise positions Alfasigma to capture full commercial value in one of the world’s largest pharmaceutical markets, rather than sharing economics with a distribution partner.
Market Impact
- China Vascular Landscape: With an aging population and rising prevalence of vascular disease, direct control of sulodexide’s promotion gives Alfasigma China greater flexibility in market access, medical education, and brand strategy.
- In‑House Model Shift: The transfer reflects a broader multinational trend of reclaiming China commercial rights from local partners as affiliates build mature in‑country capabilities.
- Growth Platform: The ~30 % scale uplift transforms Alfasigma China into a materially larger platform ahead of the €100 million revenue ambition for 2027.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the completion of the business transfer, expected incremental revenue, business expansion, and Alfasigma China’s growth targets. Actual results may differ materially due to risks including regulatory approvals, integration execution, market conditions, and competitive dynamics.-Fineline Info & Tech
